Table 2 Microbiology of patients with device-associated osteomyelitis treated with daptomycin in the CORE database
From: A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin
Pathogens, n (%)a | No follow-up in CORE 2009 | Evaluable population | |
|---|---|---|---|
PJI | OHAO | ||
(n = 32) | (n = 27) | (n = 21) | |
Staphylococcus aureus (MRSA) | 9 (28.1) | 6 (22.2) | 7 (33.3) |
Staphylococcus aureus (MSSA) | 2 (6.3) | 3 (11.1) | 4 (19.0) |
Other Staphylococcus aureus b | 1 (3.1) | 1 (3.7) | 0 (0.0) |
Coagulase-negative staphylococci | 3 (9.4) | 6 (22.2) | 3 (14.3) |
Enterococcus spp. | 4 (12.5) | 3 (11.1) | 3 (14.3) |
Vancomycin-resistant enterococci | 1 (3.1) | 1 (3.7) | 2 (9.5) |
Streptococcus spp. | 0 (0.0) | 0 (0.0) | 1 (4.8) |
Other | 7 (21.9) | 3 (11.1) | 1 (4.8) |